Lynda M. Vrooman

Publications

1. Correction to: Cancer survivorship programs at the Dana-Farber Cancer Institute. J Cancer Surviv. 2025 Jun; 19(3):1112. View Abstract
2. Help Navigate the Process: Early Information and Communication About Late Effects of Pediatric and Adolescent Cancer. JCO Oncol Pract. 2025 Mar 20; OP2400841. View Abstract
3. Impact of Persistent Alopecia on Quality of Life in Childhood Cancer and Transplant Survivors. Pediatr Blood Cancer. 2025 Feb; 72(2):e31432. View Abstract
4. Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen. Blood Cancer J. 2024 10 31; 14(1):191. View Abstract
5. Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study. Lancet Child Adolesc Health. 2024 10; 8(10):740-750. View Abstract
6. Cancer survivorship programs at the Dana-Farber Cancer Institute. J Cancer Surviv. 2024 02; 18(1):34-41. View Abstract
7. Measuring neurobehavioral side effects of corticosteroids in pediatric acute lymphoblastic leukemia: A scoping review. Pediatr Blood Cancer. 2024 Apr; 71(4):e30881. View Abstract
8. Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia. 2024 03; 38(3):482-490. View Abstract
9. Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. Blood Adv. 2023 09 26; 7(18):5234-5245. View Abstract
10. Impairment of health-related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL Consortium. Pediatr Blood Cancer. 2023 11; 70(11):e30560. View Abstract
11. Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. Blood Adv. 2023 04 11; 7(7):1092-1102. View Abstract
12. Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer. J Clin Oncol. 2023 04 20; 41(12):2248-2257. View Abstract
13. Feasibility of serial neurocognitive assessment using Cogstate during and after therapy for childhood leukemia. Support Care Cancer. 2023 Jan 10; 31(2):109. View Abstract
14. Predicting chronic morbidity in childhood cancer survivors. Nat Med. 2022 08; 28(8):1539-1540. View Abstract
15. Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. Br J Haematol. 2022 08; 198(3):421-430. View Abstract
16. Clinical Characteristics and Short-Term Outcomes of Children With Asparaginase-Associated Pancreatitis. J Pediatr Gastroenterol Nutr. 2022 Mar 01; 74(3):402-407. View Abstract
17. Cardiometabolic Risk in Childhood Cancer Survivors: A Report from the Children's Oncology Group. Cancer Epidemiol Biomarkers Prev. 2022 Mar 01; 31(3):536-542. View Abstract
18. Large Anterior Mediastinal Mass and Cardiac Infiltration at Diagnosis in a Child With T-cell Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2022 Mar 01; 44(2):e418-e419. View Abstract
19. Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. Blood Adv. 2022 01 11; 6(1):72-81. View Abstract
20. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group. Eur J Cancer. 2022 02; 162:65-75. View Abstract
21. Hyperglycemia during induction therapy for acute lymphoblastic leukemia is temporally linked to pegaspargase administration. Pediatr Blood Cancer. 2022 07; 69(7):e29505. View Abstract
22. Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group. Cancer. 2022 02 15; 128(4):788-796. View Abstract
23. Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Diabetes Endocrinol. 2021 09; 9(9):622-637. View Abstract
24. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 11 01; 39(31):3496-3505. View Abstract
25. Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia. Lancet Haematol. 2021 Jul; 8(7):e513-e523. View Abstract
26. Pediatric primary cutaneous anaplastic large cell lymphoma treated with brachytherapy. Pediatr Dermatol. 2021 May; 38(3):712-713. View Abstract
27. Virtual visits as long-term follow-up care for childhood cancer survivors: Patient and provider satisfaction during the COVID-19 pandemic. Pediatr Blood Cancer. 2021 06; 68(6):e28927. View Abstract
28. Corrigendum. Pediatr Blood Cancer. 2021 Mar; 68(3):e28885. View Abstract
29. Risk factors for steroid-induced affective disorder in children with leukemia. Pediatr Blood Cancer. 2021 05; 68(5):e28847. View Abstract
30. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 01; 68(1):e28719. View Abstract
31. Long-Term Psychosocial Well-Being and Quality of Life Among Childhood Cancer Survivors Who Developed a Subsequent Malignant Neoplasm. J Adolesc Young Adult Oncol. 2021 04; 10(2):240-245. View Abstract
32. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Adv. 2020 05 12; 4(9):2084-2094. View Abstract
33. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Adv. 2018 06 26; 2(12):1449-1458. View Abstract
34. Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. Lancet Oncol. 2017 09; 18(9):1238-1248. View Abstract
35. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1327-1334. View Abstract
36. A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017 Jul; 64(7). View Abstract
37. Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia. Support Care Cancer. 2017 02; 25(2):449-457. View Abstract
38. Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances. Curr Hematol Malig Rep. 2016 10; 11(5):385-94. View Abstract
39. Fatigue in adolescent and adult survivors of non-CNS childhood cancer: a report from project REACH. Support Care Cancer. 2016 09; 24(9):3951-9. View Abstract
40. Adapted Delivery of Cognitive-Behavioral Treatment for Insomnia in Adolescent and Young Adult Cancer Survivors: A Pilot Study. Behav Sleep Med. 2017 Jul-Aug; 15(4):288-301. View Abstract
41. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016 Mar; 101(3):279-85. View Abstract
42. Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer. 2016 Mar 15; 122(6):946-53. View Abstract
43. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec; 16(16):1677-90. View Abstract
44. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia. Pediatr Blood Cancer. 2016 Feb; 63(2):228-33. View Abstract
45. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013 Mar 20; 31(9):1202-10. View Abstract
46. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer. 2011 Jun; 47(9):1373-9. View Abstract
47. 25-hydroxy vitamin D deficiency following pediatric hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2011 May; 17(5):749-53. View Abstract
48. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010 Feb; 54(2):199-205. View Abstract
49. Health status of the oldest adult survivors of cancer during childhood. Cancer. 2010 Jan 15; 116(2):497-505. View Abstract
50. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010 Feb 18; 115(7):1351-3. View Abstract
51. Childhood acute lymphoblastic leukemia: update on prognostic factors. Curr Opin Pediatr. 2009 Feb; 21(1):1-8. View Abstract
52. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008 Mar 01; 26(7):1106-11. View Abstract
Show All Publications Show Fewer Publications